Table 1.
Association of SMARCA4 and EZH2 mRNA expression with clinico-pathological characteristics in 238 OC patients.
| Variable | Number (%) | mRNA expression values (arbitrary units) | |||
|---|---|---|---|---|---|
| SMARCA4 | EZH2 | ||||
| Median (IQR) | P value | Median (IQR) | P value | ||
| Age | |||||
| ≤ 62 years (median age) | 120 (50.4%) | 2.250 (1.74–3.35) | 0.064 | 2.135 (1.24–3.90) | 0.487 |
| > 62 years | 118 (49.6%) | 2.056 (1.46–2.85) | 2.185 (1.32–3.03) | ||
| ≤ 51.5 years | 53 (22.3%) | 2.187 (1.63–3.54) | 0.381 | 1.660 (0.75–3.91) | 0.060 |
| > 51.5 years | 185 (77.7%) | 2.099 (1.56–2.87) | 2.300 (1.49–3.24) | ||
| ≤ 70 years | 167 (70.2%) | 2.219 (1.71–3.20) | 0.028 | 2.270 (1.41–3.73) | 0.168 |
| > 70 years | 71 (29.8%) | 2.005 (1.32–2.81) | 1.940 (1.25–2.94) | ||
| ≤ 40 years | 14 (5.9%) | 1.961 (1.13–2.46) | 0.151 | 1.155 (0.66–1.90) | 0.004 |
| > 40 years | 224 (94.1%) | 2.163 (1.61–3.04) | 2.255 (1.47–3.36) | ||
| Histology | |||||
| HGSOC | 144 (60.5%) | 2.250 (1.72–3.07) | 0.695 | 2.390 (1.51–3.69) | < 0.001 |
| LGSOC | 12 (5.0%) | 1.876 (1.53–2.48) | 0.710 (0.56–1.52) | ||
| HGEOC | 31 (13.0%) | 2.392 (1.15–3.98) | 2.530 (1.78–5.39) | ||
| LGEOC | 13 (5.5%) | 2.093 (1.76–2.55) | 2.520 (1.59–3.16) | ||
| Clear cell OC | 11 (4.6%) | 2.216 (1.13–3.33) | 1.310 (0.86–2.88) | ||
| Mucinous OC | 27 (11.3%) | 2.123 (1.44–3.08) | 1.570 (0.80–2.56) | ||
| FIGO stage | |||||
| I/II | 64 (26.9%) | 2.313 (1.58–3.35) | 0.193 | 2.125 (1.27–3.10) | 0.659 |
| III/IV | 174 (73.1%) | 2.082 (1.57–2.89) | 2.185 (1.39–3.41) | ||
| Tumor grade | |||||
| Low grade | 30 (12.6%) | 1.915 (1.55–2.47) | 0.145 | 1.410 (0.68–2.54) | 0.001 |
| Grade III | 208 (87.4%) | 2.219 (1.58–3.09) | 2.320 (1.48–3.58) | ||
| Residual disease | |||||
| Complete debulking | 114 (47.9%) | 2.219 (1.69–3.37) | 0.044 | 2.125 (1.19–3.29) | 0.647 |
| Any residual | 114 (47.9%) | 2.076 (1.48–2.76) | 2.185 (1.48–3.33) | ||
| Not indicated | 10 (4.2%) | – | – | ||
| Subgroups | |||||
| “Low-grade OC” | 25 (11.8%) | 1.917 (1.61–2.50) | 0.188 | 1.590 (0.71–2.61) | 0.006 |
| “High-grade OC” | 186 (88.2%) | 2.250 (1.65–3.08) | 2.410 (1.52–3.87) | ||
| BRCA1 mutation status | |||||
| Wild-type | 155 (65.1%) | 2.093 (1.64–2.87) | 0.587 | 2.060 (1.25–3.22) | 0.013 |
| BRCA1 mutated | 35 (14.7%) | 2.437 (1.79–3.20) | 3.070 (1.90–4.51) | ||
| Not indicated | 48 (20.2%) | – | – | ||
| BRCA2 mutation status | |||||
| Wild-type | 181 (76.0%) | 2.111 (1.65–2.89) | 0.787 | 2.240 (1.41–3.29) | 0.313 |
| BRCA2 mutated | 9 (3.8%) | 1.904 (1.55–3.37) | 3.910 (1.10–7.05) | ||
| Not indicated | 48 (20.2%) | – | – | ||
IQR interquartile range.
Bold values indicate P < 0.05.